Trial Profile

Phase I-II Trial, Open and Non-Randomized, to Assess the Role of Idelalisib in Patients With Acute Lymphoblastic Leukemia (ALL) Relapsed or Refractory to Other Treatments, and in Elderly Patients With ALL in Which it is Advised Against the use of Conventional Therapies

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 07 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Feb 2021 Status changed from recruiting to discontinued.
19 May 2020 Planned primary completion date changed from 1 Jun 2020 to 7 Jul 2020.
27 Apr 2020 Planned primary completion date changed from 1 Jan 2020 to 1 Jun 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com